Abstract 105P
Background
Cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-Seq) is a promising approach to assess non-invasive methylomics. Despite its cost-efficiency and accuracy, the setup and processing of cfMeDIP-Seq are technically challenging. The original protocol developed by Shen et al. in 2019 can now be partially automated, potentially improving reproducibility and yield.
Methods
We designed a pilot study to evaluate the performance of cfMeDIP-Seq under 4 library preparation conditions. We collected 4 K2EDTA and 4 PAXgene ccfDNA tubes (BD Vacutainer™) from the same healthy donor. We processed K2EDTA and PAXgene tubes within 2 and 6 hours of blood draw respectively, as previously described (Dameri et al., 2023). We used 10 ng of cfDNA for library preparation. Each condition underwent 2 parallel preparation procedures: one following the manual protocol described by Shen et al., and the other following a semi-automated version of the original protocol using the IP-Star® Compact instrument (Diagenode). We generated a total of 16 libraries, 4 for each condition, and sequenced them on Illumina NovaSeq 6000 device.
Results
The number of uniquely mapped reads was comparable (p-value = 0.8) between semi-automated and manually processed libraries, with an average of 19.9 MReads per sample. The percentage of duplicates was reduced (p-value = 0.0012) in semi-automated libraries (median = 32.88; IQR = 31.94-34.06) compared to manually prepared ones (median = 41.48; IQR = 35.61-42.53). Semi-automated libraries showed a longer mean insert size (255 bp) compared to manually processed libraries (243 bp) with a p-value < 0.01. Principal component analysis revealed no major differences between K2EDTA and PAXgene samples processed with the semi-automated protocol. We observed no significant differences across the 4 conditions in terms of GC content (47%, sd = 0.49).
Conclusions
In the present pilot study, we demonstrated that semi-automated library preparation outperformed the fully manual protocol, regardless of tube type but provided that K2EDTA were processed shortly after collection. Partial automation of fluidic handling seems extremely relevant to increase yield and quality of cfMeDIP-Seq experiments.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Associazione Italiana per la Ricerca sul Cancro (AIRC) and 5x1000 by Italian Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract